Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Obstetrics and gynaecology indexChapter sections
Role and principlesAssessment and patient selectionBaseline assessmentInterventionsMedicines and treatment safetyTargets, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Anti-D prophylaxis principles in early pregnancy

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Treat the bleeding emergency first

Anti-D never replaces resuscitation, urgent imaging or operative control of a ruptured ectopic pregnancy or major miscarriage haemorrhage.

Action: Use an ABCDE approach, obtain senior gynaecology and anaesthetic help, activate the major-haemorrhage pathway when indicated, then revisit RhD prophylaxis once immediate danger is controlled.

Role and principles

Apply the June 2026 NICE anti-D thresholds accurately, explain sensitisation and consent simply, and prevent both unnecessary treatment before 12 weeks and missed prophylaxis at 12 weeks.

RhD alloimmunisation occurs when an RhD-negative person encounters RhD-positive fetal erythrocytes and mounts an immune response. IgG anti-D in a later RhD-positive pregnancy can cross the placenta, destroy fetal red cells and cause fetal anaemia, hydrops, neonatal jaundice or perinatal death. Passive anti-D immunoglobulin binds RhD-positive cells before an effective maternal immune response develops; it prevents sensitisation but does not remove established immune anti-D.

NICE NG126 was updated on 17 June 2026 because evidence does not show benefit from anti-D for ectopic pregnancy or miscarriage before 12+0 weeks and sensitisation at this stage is very uncommon. The result is a gestation-led decision: none through 11+6 weeks; offer prophylaxis at 12+0 to 12+6 for medical or surgical management; and consider it for threatened miscarriage at those gestations when bleeding is heavy or recurrent.

Eligibility is narrower than simply finding an RhD-negative result. Confirm the pregnancy event, use the most accurate gestational estimate, establish whether the person is already sensitised, and check what treatment is occurring. Explain uncertainty, the plasma-derived nature of the product and alternatives without allowing testing or supply to delay time-critical care.

Assessment and patient selection

Gestational boundary

Write gestation as weeks plus days. The operational boundary is 11+6 versus 12+0; an imprecise label such as twelve weeks can generate the wrong decision.

Event and treatment

Distinguish threatened miscarriage with an ongoing intrauterine pregnancy from confirmed miscarriage or ectopic pregnancy, then record whether management is medical, surgical or expectant.

RhD and sensitisation status

Prophylaxis is relevant to an RhD-negative person without established immune anti-D. A positive antibody screen needs blood-bank interpretation because recent passive anti-D and immune anti-D have different implications.

Bleeding burden

For threatened miscarriage at 12+0 to 12+6, ask about pad saturation, clots, duration, recurrence, pain and haemodynamic symptoms; NICE intentionally leaves heavy or recurrent to clinical judgement.

Consent preferences

Ask about beliefs, previous reactions and concerns about plasma products in private, use a professional interpreter when required, and allow a capacitous person to accept or decline.

Red flags requiring action

  • Syncope, shoulder-tip pain, severe unilateral pelvic pain or peritonism suggesting a ruptured ectopic pregnancy.
  • Tachycardia, hypotension, pallor, confusion or ongoing heavy bleeding indicating clinically important blood loss.
  • Fever, offensive discharge, uterine tenderness or systemic illness suggesting infected miscarriage or sepsis.

Baseline assessment

  1. 01
    Ultrasound datingFirst step
    Why
    Establish the best gestational estimate and pregnancy location or viability where clinically required.
    Interpretation and limitations
    When ultrasound dating and last menstrual period disagree, NICE directs clinicians to use ultrasound for the anti-D decision. Imaging must still be interpreted within the PUL or miscarriage pathway rather than as an anti-D test.
  2. 02
    ABO and RhD group
    Why
    Identify whether RhD prophylaxis could be relevant without delaying emergency treatment.
    Interpretation and limitations
    A confirmed RhD-positive result means anti-D is unnecessary. An RhD-negative result triggers assessment against gestation and event thresholds, not automatic injection below 12 weeks.
  3. 03
    Red-cell antibody screen
    Why
    Detect pre-existing immune anti-D and clinically important non-D antibodies.
    Interpretation and limitations
    Established immune anti-D means prophylaxis cannot undo sensitisation and requires specialist pregnancy planning. Liaise with transfusion laboratory to distinguish immune antibody from transient passive antibody after a documented dose.
  4. 04
    Full blood count and group-and-save
    Why
    Assess significant bleeding and prepare safe transfusion support when the presentation demands it.
    Interpretation and limitations
    Haemoglobin may initially appear normal in acute blood loss, so vital signs and continuing loss take priority. These tests address haemorrhage risk; they

Interventions

01Up to 11+6 weeksDo not offer anti-DFirst stepUltrasound gestation is no more than 11+6 weeks and the event is ectopic pregnancy, miscarriage or threatened miscarriage.+
  1. 1Manage pain, bleeding, pregnancy location and viability through the appropriate urgent or early-pregnancy pathway.
  2. 2Do not prescribe anti-D, including after manual vacuum aspiration, laparoscopy or other surgical management below 12+0 weeks.
  3. 3Explain that the 2026 recommendation reflects extremely low sensitisation risk and lack of demonstrated benefit, and document gestation and advice.
0212+0 to 12+6 interventionOffer the minimum effective doseAn RhD-negative, non-sensitised person at 12+0 to 12+6 weeks is having medical management or a surgical procedure for ectopic pregnancy or miscarriage.+
  1. 1Confirm the event, ultrasound gestation, RhD result and absence of established immune anti-D while treatment planning continues.

Medicines and treatment safety

Provides passive anti-D that removes or masks RhD-positive fetal erythrocytes before a non-sensitised RhD-negative recipient develops an active immune response.

Anti-D immunoglobulin

At 12+0 to 12+6 weeks give at least 250 IU (50 micrograms), using the authorised intramuscular or intravenous route for the selected product; a larger stocked dose may be used when the minimum-size vial is unavailable.

Do not offer through 11+6 weeks for ectopic pregnancy, miscarriage or threatened miscarriage; do not use as treatment for established immune anti-D; check product allergy and IgA-related reaction history, obtain consent for a human-plasma product and observe according to the product protocol.

Targets, monitoring and follow-up

  • Record the ultrasound gestation, event, management type, RhD group, antibody result and exact rationale at the point of decision.
  • After administration document product name, batch number, expiry, dose, route, site and time to preserve haemovigilance traceability.
  • Observe for immediate hypersensitivity according to the product information and treat anaphylaxis promptly if airway, breathing or circulatory features develop.
  • Ensure that an early-pregnancy dose does not replace routine antenatal antibody screening, routine antenatal prophylaxis or prophylaxis after later sensitising events.
  • If immune anti-D is detected, arrange specialist antibody quantification and fetal-risk planning instead of repeatedly issuing prophylactic doses.
  • Audit use below 12 weeks because persistent application of the superseded surgical exception exposes patients to an unnecessary blood product.

Special situations

The surgical exception has gone

The June 2026 NICE update specifically removes routine anti-D after surgical treatment of ectopic pregnancy or miscarriage through 11+6 weeks.

Ultrasound resolves dating conflict

When menstrual and ultrasound gestations differ across the 12+0 boundary, the ultrasound estimate governs prophylaxis under NG126.

At least means minimum

NICE chose 250 IU as the lowest acceptable dose and permits a larger stocked presentation when 250 IU is unavailable.

Passive is not therapeutic

Anti-D prevents a new immune response; it does not clear established maternal immune anti-D or treat fetal anaemia.

Consent needs material facts

The essential product explanation is that anti-D is a filtered protein from human plasma and contains no blood cells.

Common pitfalls

  1. 01

    Following a pre-June-2026 rule and giving anti-D after surgery at 10 weeks.

  2. 02

    Writing twelve weeks without days and missing the decisive 11+6 to 12+0 boundary.

  3. 03

    Using last menstrual period when ultrasound supplies a conflicting and more accurate gestational estimate.

  4. 04

    Automatically giving anti-D for every episode of light threatened bleeding at 12 weeks without clinical judgement.

  5. 05

    Ordering Kleihauer testing and delaying prophylaxis or urgent management while awaiting the result.

  6. 06

    Failing to distinguish prophylaxis for a non-sensitised person from fetal-medicine care for established immune anti-D.

  7. 07

    Describing anti-D as not a blood product rather than accurately explaining its filtered human-plasma origin.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA

Surgery below twelve weeks

An RhD-negative, non-sensitised patient has surgical management of a confirmed ectopic pregnancy at ultrasound gestation 10+5 weeks. What does current NICE guidance recommend about anti-D?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Obstetrics and gynaecology topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG126 anti-D prophylaxisCurrent gestational thresholds, minimum dose, consent information and Kleihauer recommendation.
  • NICE NG126 update informationConfirms the June 2026 evidence review and change from earlier practice.
  • NICE anti-D resource impactImplementation implications of removing prophylaxis through 11+6 weeks.
  • NICE routine antenatal anti-DPlaces event prophylaxis within the wider prevention of RhD sensitisation.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Key points

  • Anti-D immunoglobulin prevents an RhD-negative, non-sensitised pregnant person forming immune anti-D after exposure to RhD-positive fetal red cells.
  • Do not offer anti-D for ectopic pregnancy, miscarriage or threatened miscarriage up to and including 11+6 weeks, even after surgical management.
  • Use ultrasound gestation rather than the last menstrual period when the two estimates disagree.
  • At 12+0 to 12+6 weeks, offer at least 250 IU (50 micrograms) after medical or surgical management of ectopic pregnancy or miscarriage.
  • At 12+0 to 12+6 weeks with threatened miscarriage, consider at least 250 IU when bleeding is heavy or recurrent; clinical judgement defines that bleeding.
  • Explain that anti-D is a filtered protein obtained from human plasma and contains no blood cells, then obtain and document informed consent.
  • Do not order a Kleihauer test to quantify fetomaternal haemorrhage in this early-pregnancy pathway.
  • The June 2026 recommendation reverses older practice that routinely gave anti-D after first-trimester surgical management below 12 weeks.
Previous immune anti-D antibodies, which require specialist fetal-medicine assessment rather than prophylactic anti-D alone.
  • A transfusion reaction pattern after administration, including airway swelling, wheeze, hypotension or rapidly spreading urticaria.
    • do not
    decide prophylaxis on their own.
  • 05
    Kleihauer test
    Why
    Recognise a test that should not be used in this early-pregnancy context.
    Interpretation and limitations
    NICE states not to quantify fetomaternal haemorrhage with Kleihauer testing for early ectopic pregnancy or miscarriage. Do not delay the indicated minimum dose while awaiting it.
    • 2
    Discuss benefits, uncertainty, plasma origin and alternatives, then offer at least 250 IU (50 micrograms); a larger available vial is acceptable because 250 IU is the minimum.
  • 3Administer by the product-authorised route within the service pathway, record product, batch, dose, route and time, and provide reaction advice.
    • 0312+0 to 12+6 threatened lossJudge heavy or recurrent bleedingThe pregnancy remains potentially viable, the person is RhD-negative and bleeding at 12+0 to 12+6 weeks is heavy or recurrent.+
    1. 1EscalationAssess haemodynamic stability, pain and pregnancy location before focusing on prophylaxis; escalate any ectopic or haemorrhage concern.
    2. 2Use the history and observed bleeding to decide whether heavy or recurrent applies, acknowledging that NICE supplies no numerical pad threshold.
    3. 3Consider and discuss at least 250 IU (50 micrograms), record the reasoning whether given or not, and continue viability follow-up.
    04Immune anti-D or declined productRespect choice and escalate expertiseEscalationThe antibody screen suggests established sensitisation, the result is uncertain, or a capacitous person declines the plasma-derived product.+
    1. 1Ask the transfusion laboratory to classify the antibody and refer established immune anti-D to obstetric or fetal-medicine care.
    2. 2Explore questions without pressure, explain that the product is filtered human-plasma protein without blood cells, and offer time or specialist discussion when safe.
    3. 3Document the information, decision and contingency plan; do not administer covertly or treat refusal as loss of access to other care.